Menu
No results found.
Weekly Share Price & Valuation Overview
Astellas Pharma Inc.
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD); EVRENZO, a treatment for anemia associated with chronic kidney disease (CKD); Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants. The company has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Chuo, Japan.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- JPY 2.99T
- Enterprise Value Operating value: market cap + total debt − cash.
- JPY 3.67T
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- JPY 1.94T
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- JPY 1.59T
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- JPY 485.44B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- JPY 1.09K
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 28.24
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 4.67%
- Shares Outstanding
- 1.79B
- Float Shares
- 1.75B
- Implied Shares Outstanding
- 1.79B
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
20.57%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
24.96%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
81.86%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
4.19%
- ROA Return on assets: net income ÷ total assets.
-
5.10%
- ROE Return on equity: net income ÷ shareholder equity.
-
5.17%
- Revenue Growth Year-over-year revenue growth.
-
6.90%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
82.00%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
82.00%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.81
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.60
- Total Cash Cash and equivalents.
- JPY 215.40B
- Total Debt Short + long-term interest-bearing debt.
- JPY 889.49B
- Net Debt Total debt − cash (negative = net cash).
- JPY 674.09B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 1.83
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- JPY 236.75B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- JPY 129.92B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
12.17%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
6.68%
- Cash Conversion (OpCF/EBITDA)
- 0.49
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.